137 related articles for article (PubMed ID: 26434941)
1. Combinatorial therapy for triple negative breast cancer using hyperstar polymer-based nanoparticles.
Misra SK; Wang X; Srivastava I; Imgruet MK; Graff RW; Ohoka A; Kampert TL; Gao H; Pan D
Chem Commun (Camb); 2015 Dec; 51(93):16710-3. PubMed ID: 26434941
[TBL] [Abstract][Full Text] [Related]
2. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice.
Zhang T; Prasad P; Cai P; He C; Shan D; Rauth AM; Wu XY
Acta Pharmacol Sin; 2017 Jun; 38(6):835-847. PubMed ID: 28216624
[TBL] [Abstract][Full Text] [Related]
3. Identification of galiellalactone-based novel STAT3-selective inhibitors with cytotoxic activities against triple-negative breast cancer cell lines.
Kim HS; Kim T; Ko H; Lee J; Kim YS; Suh YG
Bioorg Med Chem; 2017 Oct; 25(19):5032-5040. PubMed ID: 28705432
[TBL] [Abstract][Full Text] [Related]
4. Pyrimethamine conjugated histone deacetylase inhibitors: Design, synthesis and evidence for triple negative breast cancer selective cytotoxicity.
Wu B; Fathi S; Mortley S; Mohiuddin M; Jang YC; Oyelere AK
Bioorg Med Chem; 2020 Mar; 28(6):115345. PubMed ID: 32061484
[TBL] [Abstract][Full Text] [Related]
5. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library.
Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M
Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable ZnO@polymer core-shell nanocarriers: pH-triggered release of doxorubicin in vitro.
Zhang ZY; Xu YD; Ma YY; Qiu LL; Wang Y; Kong JL; Xiong HM
Angew Chem Int Ed Engl; 2013 Apr; 52(15):4127-31. PubMed ID: 23463695
[No Abstract] [Full Text] [Related]
7. A PDA-DTC/Cu-MnO
Hu X; Lu Y; Zhao W; Sun M; Li R; Feng L; Yao T; Dong C; Shi S
Chem Commun (Camb); 2021 Apr; 57(34):4158-4161. PubMed ID: 33908477
[TBL] [Abstract][Full Text] [Related]
8. Discovery and SAR studies of novel 2-anilinopyrimidine-based selective inhibitors against triple-negative breast cancer cell line MDA-MB-468.
Jo J; Kim SH; Kim H; Jeong M; Kwak JH; Taek Han Y; Jeong JY; Jung YS; Yun H
Bioorg Med Chem Lett; 2019 Jan; 29(1):62-65. PubMed ID: 30447889
[TBL] [Abstract][Full Text] [Related]
9. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.
Du JZ; Du XJ; Mao CQ; Wang J
J Am Chem Soc; 2011 Nov; 133(44):17560-3. PubMed ID: 21985458
[TBL] [Abstract][Full Text] [Related]
10. Multi-layered polymeric nanoparticles for pH-responsive and sequenced release of theranostic agents.
Wang H; Zhao S; Agarwal P; Dumbleton J; Yu J; Lu X; He X
Chem Commun (Camb); 2015 May; 51(36):7733-6. PubMed ID: 25850616
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
12. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
Hall SR; Toulany J; Bennett LG; Martinez-Farina CF; Robertson AW; Jakeman DL; Goralski KB
J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004
[TBL] [Abstract][Full Text] [Related]
13. Targeting a cell state common to triple-negative breast cancers.
Muellner MK; Mair B; Ibrahim Y; Kerzendorfer C; Lechtermann H; Trefzer C; Klepsch F; Müller AC; Leitner E; Macho-Maschler S; Superti-Furga G; Bennett KL; Baselga J; Rix U; Kubicek S; Colinge J; Serra V; Nijman SM
Mol Syst Biol; 2015 Feb; 11(1):789. PubMed ID: 25699542
[TBL] [Abstract][Full Text] [Related]
14. Mapping Novel Metabolic Nodes Targeted by Anti-Cancer Drugs that Impair Triple-Negative Breast Cancer Pathogenicity.
Roberts LS; Yan P; Bateman LA; Nomura DK
ACS Chem Biol; 2017 Apr; 12(4):1133-1140. PubMed ID: 28248089
[TBL] [Abstract][Full Text] [Related]
15. DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer.
Pindiprolu SKSS; Krishnamurthy PT; Dev C; Chintamaneni PK
Chem Phys Lipids; 2021 Mar; 235():105033. PubMed ID: 33385372
[TBL] [Abstract][Full Text] [Related]
16. Discovery of N-(Naphtho[1,2-b]Furan-5-Yl) Benzenesulfonamides as Novel Selective Inhibitors of Triple-Negative Breast Cancer (TNBC).
Chen Y; Tang Y; Mao B; Li W; Jin H; Zhang L; Liu Z
Molecules; 2018 Mar; 23(3):. PubMed ID: 29547591
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol loaded oxidized mesoporous carbon nanoparticles: A promising tool to treat triple negative breast cancer.
Fan C; Kong F; Shetti D; Zhang B; Yang Y; Wei K
Biochem Biophys Res Commun; 2019 Nov; 519(2):378-384. PubMed ID: 31519327
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q
Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520
[TBL] [Abstract][Full Text] [Related]
19. Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation of the Therapeutic Efficacy In vitro.
Eskiler GG; Cecener G; Dikmen G; Egeli U; Tunca B
Curr Drug Deliv; 2019; 16(6):511-529. PubMed ID: 31113350
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and structure-activity relationship studies of a focused library of pyrimidine moiety with anti-proliferative and anti-metastasis activities in triple negative breast cancer.
Yao D; Zhou Y; Zhu L; Ouyang L; Zhang J; Jiang Y; Zhao Y; Sun D; Yang S; Yu Y; Wang J
Eur J Med Chem; 2017 Nov; 140():155-171. PubMed ID: 28923383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
